Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Last updated: February 4, 2013
Sponsor: Bausch & Lomb Incorporated
Overall Status: Completed

Phase

3

Condition

Allergy (Pediatric)

Allergy

Allergies & Asthma

Treatment

N/A

Clinical Study ID

NCT00586664
CL-S&E-0409071-P
  • Ages > 10
  • All Genders

Study Summary

Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects must be at least 10 years of age

Exclusion

Exclusion Criteria:

  • No active ocular disease

Study Design

Total Participants: 130
Study Start date:
October 01, 2007
Estimated Completion Date:
June 30, 2008

Connect with a study center

  • ISTA Pharmaceuticals, Inc.

    Irvine, California 92618
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.